A retrospective single-center study to compare the efficacy and safety of Filgrastim biosimilar (Nivestim) to Filgrastim (Neupogen) in relation to autologous peripheral blood stem cells mobilization and engraftment in patients with multiple myeloma undergoing autologous stem cell transplantation

Trial Profile

A retrospective single-center study to compare the efficacy and safety of Filgrastim biosimilar (Nivestim) to Filgrastim (Neupogen) in relation to autologous peripheral blood stem cells mobilization and engraftment in patients with multiple myeloma undergoing autologous stem cell transplantation

Completed
Phase of Trial: Phase IV

Latest Information Update: 04 Apr 2016

At a glance

  • Drugs Filgrastim (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 04 Apr 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top